Research map: Hinge Region Cys-to-Ser Mutation Enables Homogeneous DAR6 Anti-c-Met Biparatopic ADCs with Tolerable O-Glycosylation

Back to the article

Papers in this map

  1. Met, metastasis, motility and more · Carmen Birchmeier · 2003 · 2619 citations · Cited by this paper
  2. The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates · 2026 · Related
  3. Targeting MET in cancer: rationale and progress · Ermanno Gherardi · 2012 · 1435 citations · Cited by this paper
  4. Beyond Affinity: AI-Supported Developability Assessment and Multi-Objective Optimization in Antibody Development · 2026 · Related
  5. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index · Jagath Reddy Junutula · 2008 · 1390 citations · Cited by this paper
  6. Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF-PD-1 antibody ivonescimab · 2026 · Related
  7. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates · Ben‐Quan Shen · 2012 · 1020 citations · Cited by this paper
  8. Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression · 2026 · Related
  9. Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family · Eric Bennett · 2011 · 904 citations · Cited by this paper
  10. Delivery devices and container closure systems for co-formulated and co-administered biologics · 2026 · Related
  11. Mechanisms and principles of N-linked protein glycosylation · Flavio Schwarz · 2011 · 713 citations · Cited by this paper
  12. Integrative and Emerging Models in Antibody Research: A Comprehensive Review · 2025 · Related
  13. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases · Kelly G. Ten Hagen · 2002 · 501 citations · Cited by this paper
  14. Why antibody isotype matters for immunotherapy · 2026 · Related
  15. Glycosylation: mechanisms, biological functions and clinical implications · Mengyuan He · 2024 · 479 citations · Cited by this paper
  16. Design and Therapeutic Rationale of Antibody-Peptide Conjugates: Insights from Maridebart Cafraglutide (AMG133) and Emerging Applications · 2025 · Related
  17. The Glycosylation and Structure of Human Serum IgA1, Fab, and Fc Regions and the Role of N-Glycosylation on Fcα Receptor Interactions · Taj S. Mattu · 1998 · 405 citations · Cited by this paper
  18. Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development · 2025 · Related
  19. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer · Neha M. Akella · 2019 · 387 citations · Cited by this paper
  20. Analysis of the use of monoclonal antibodies in the treatment of Crohn’s disease · 2026 · Related
  21. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial · Fabrice André · 2023 · 374 citations · Cited by this paper
  22. MET-dependent solid tumours — molecular diagnosis and targeted therapy · Robin Guo · 2020 · 335 citations · Cited by this paper
  23. Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer · Jagath Reddy Junutula · 2010 · 295 citations · Cited by this paper
  24. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment · Charlotte Fenton McDonagh · 2006 · 243 citations · Cited by this paper
  25. Targeting MET Dysregulation in Cancer · Gonzalo Recondo · 2020 · 231 citations · Cited by this paper
  26. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC · Gonzalo Recondo · 2020 · 229 citations · Cited by this paper
  27. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency · Roger R. Beerli · 2015 · 228 citations · Cited by this paper
  28. Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity · Benjamin Peschke · 2017 · 226 citations · Cited by this paper
  29. HGF/SF-Met signaling in tumor progression · Chong Gao · 2005 · 175 citations · Cited by this paper
  30. Methods in Enzymology: O‐Glycosylation of Proteins · Jasna Peter‐Katalinić · 2005 · 164 citations · Cited by this paper
  31. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer · Charles E. Geyer · 2025 · 148 citations · Cited by this paper
  32. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors · John H. Strickler · 2018 · 145 citations · Cited by this paper
  33. Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential · Florian Cymer · 2017 · 139 citations · Cited by this paper
  34. Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit · Hartmut Koeppen · 2014 · 136 citations · Cited by this paper
  35. Tissue-Specific Glycosylation at the Glycopeptide Level · Katalin F. Medzihradszky · 2015 · 126 citations · Cited by this paper
  36. Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3) · Rosina Plomp · 2015 · 125 citations · Cited by this paper
  37. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) · Cristina Saura · 2023 · 119 citations · Cited by this paper
  38. MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy · Henning Reis · 2018 · 111 citations · Cited by this paper
  39. Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering · Thomas H. Pillow · 2014 · 109 citations · Cited by this paper

Source: OpenAlex (CC0)